ViDia Christliche Kliniken Karlsruhe, Frauenklinik
Welcome,         Profile    Billing    Logout  
 1 Trial 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tomé, Oliver
SASCIA, NCT04595565 / 2019-004100-35: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting
3
1332
Europe
Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy
German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER
HER2-negative Breast Cancer, Triple Negative Breast Cancer
03/27
03/29
ECLAT, NCT03438474: Endometrial Cancer Lymphadenectomy Trial

Recruiting
N/A
640
Europe, Japan, RoW
Standard surgical procedure for endometrial cancer, systematic lymphadenectomy (LNE)
Philipps University Marburg, German Cancer Aid
Cancer of Endometrium Stage I, Cancer of Endometrium Stage II
02/28
02/29
PROOFS, NCT05792150: -Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS

Recruiting
N/A
1470
Europe
West German Study Group, Agendia
Female Breast Cancer
03/35
06/35
Tuschy, Benjamin
SAXO, NCT05042453: Long-term Evaluation of the Efficacy and Safety of Splentis for the Treatment of Primary Apical Pelvic Organ Prolapse

Recruiting
N/A
140
Europe
Splentis® POP Tissue Anchoring System
Promedon
Pelvic Organ Prolapse
07/26
07/30
ECLAT, NCT03438474: Endometrial Cancer Lymphadenectomy Trial

Recruiting
N/A
640
Europe, Japan, RoW
Standard surgical procedure for endometrial cancer, systematic lymphadenectomy (LNE)
Philipps University Marburg, German Cancer Aid
Cancer of Endometrium Stage I, Cancer of Endometrium Stage II
02/28
02/29

Download Options